-- Orthocell's (ASX:OCC) fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.
Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.
Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.
The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.